Hetero Labs Limited Fenofibrate Export Data — India (DGFT 2022–2026)

Name: Hetero Labs Limited Fenofibrate Export Records India — #2 Exporter, 338 Shipments, $8.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Fenofibrate

India Pharmaceutical Trade Intelligence

$73.4M168 Suppliers81 CountriesHS 30049099

ExportsIndia → UNITED STATES43.4%India → BELGIUM8.7%

ImportsUNITED STATES → India$13.3K CANADA → India$3.1K

#1 Buyer: YUSEN LOGISTICS

Hetero Labs Limited — Fenofibrate Exporter #2 | $8.3M Trade Value | TransData Nexus | TransData Nexus

Hetero Labs Limited — Fenofibrate Exporter Profile

Indian Pharmaceutical Exporter · #2 for Fenofibrate · $8.3M export value · DGFT Verified

Hetero Labs Limited is the #2 Indian exporter of Fenofibrate with $8.3M in export value and 338 verified shipments. Hetero Labs Limited holds a 11.3% market share in Fenofibrate exports across 8 countries. The company exports 46 pharmaceutical products worth $319.3M across 18 therapeutic categories.

Hetero Labs Limited — Fenofibrate Export Profile: Buyers & Destinations

Hetero Labs Limited Fenofibrate export treemap — buyers and destination countries | TransData Nexus

Where Does Hetero Labs Limited Export Fenofibrate?

Country	Value	Shipments	Share
UNITED STATES	$3.5M	224	52.4%
AUSTRALIA	$1.5M	38	22.1%
SAUDI ARABIA	$871.3K	33	13.1%
OMAN	$464.3K	22	7.0%
VIETNAM, DEMOCRATIC REP. OF

Who Are the Top Buyers of Fenofibrate from Hetero Labs Limited?

Buyer	Country	Value	Orders
TO THE ORDER OF	UNITED STATES	$1.7M	91
TO THE ORDER OF....	UNITED STATES	$1.0M	72
TO THE ORDER	VIETNAM	$721.1K	24
SAUDI AMAROX FOR INDUSTRY COMPANY	SAUDI ARABIA	$502.9K	18
CAMBER PHARMACEUTICALS INC	UNITED STATES	$470.2K	42
SANDOZ PTY LTD	AUSTRALIA	$363.9K	10
TO THE ORDER OF :	UNITED STATES	$350.1K	13
SADDOZ PTY LTD	AUSTRALIA	$229.9K	6
M/S	AUSTRALIA	$200.0K	4
OMAN PHARMACEUTICAL PRODUCTS CO. LL	OMAN	$152.0K	9

Hetero Labs Limited supplies Fenofibrate to 29 buyers globally. The largest buyer is TO THE ORDER OF (UNITED STATES), followed by TO THE ORDER OF.... (UNITED STATES) and TO THE ORDER (VIETNAM). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Fenofibrate Formulations Does Hetero Labs Limited Export?

Product Description / Formulation	Value	Shipments
FENOFIBRATE TABLET	$1.4M	73
FENOFIBRATE 145MG TABLET	$566.0K	26
FENOFIBRATE TABLETNOS	$410.0K	36
LIPOFIRATE (FENOFIBRATE 145MG TABLET)	$307.4K	10
FENOFIBRATE TABS	$257.0K	9
FENOFIBRATE SANDOZ 145MG (FENOFIBRATE 14	$200.0K	4
FENOFIBRATE 145MG TABLETNOS	$186.3K	24
NOLIP FENOFIBRATE 145MG TABLET 10S	$135.7K	6
FENOFIBRATE 145 MG TABS (PACK OF 90 NOS)	$134.7K	7
FIBROFIN FENOFIBRATE TABLET	$132.0K	7

Hetero Labs Limited exports 99 distinct Fenofibrate formulations including tablets, capsules, syrups, and combination drugs. The top formulation is FENOFIBRATE TABLET with 73 shipments worth $1.4M.

How Does Hetero Labs Limited Compare to Nearest Fenofibrate Exporters?

Exporters ranked immediately above and below #2 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
2	HETERO LABS LIMITED ★	$8.3M	338	8	$24.4K
3	CIPLA LIMITED	$7.1M	329	3	$21.7K
4	SUN PHARMACEUTICAL INDUSTRIES LIMITED	$5.7M	113	10	$50.0K

Hetero Labs Limited ranks #2 among 168 Indian Fenofibrate exporters. Average shipment value of $24.4K compared to the market average of $286.5K. The closest competitors by value are CIPLA LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED.

Which Indian Ports Ship Fenofibrate Exports?

Port	Shipments	% Share
NHAVA SHEVA SEA (INNSA1)	361	12.9%
SAHAR AIR	281	10.1%
SAHAR AIR CARGO ACC (INBOM4)	229	8.2%
DELHI AIR CARGO ACC (INDEL4)	227	8.1%
JNPT/ NHAVA SHEVA SEA	203	7.3%
DELHI AIR	143	5.1%
HYDERABAD ICD	125	4.5%
JNPT	115	4.1%

Geopolitical & Trade Policy Impact on Hetero Labs Limited's Fenofibrate Exports

The current geopolitical climate presents both challenges and opportunities for Hetero Labs Limited. The Israel-Iran tensions have led to increased risks in the Red Sea shipping routes, prompting major shipping lines to implement 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU. This escalation in shipping costs directly impacts Indian pharmaceutical exporters like Hetero, potentially eroding profit margins and necessitating strategic adjustments in logistics and pricing strategies.

Conversely, the U.S.-China trade tensions have created openings for Indian pharmaceutical companies. The U.S. has imposed tariffs as high as 245% on APIs from certain countries, leading to a reshoring of pharmaceutical manufacturing. Indian firms, including Hetero, have responded by investing in U.S. facilities, with outbound foreign direct investment estimated between $500-700 million during the partial FY 2025-26. This strategic move not only circumvents tariffs but also strengthens Hetero's presence in the lucrative U.S. market.

The recent India-European Union Free Trade Agreement (FTA), concluded in January 2026, eliminates tariffs on Indian pharmaceuticals entering the EU. This development enhances Hetero's competitiveness in the European market, providing a significant boost to its export potential. However, compliance with the EU's Falsified Medicines Directive remains imperative, necessitating stringent quality controls and traceability measures to maintain market access.

Hetero Labs Limited — Regulatory Compliance & Quality Standards

Regulatory compliance is paramount for Hetero's sustained success in international markets. In October 2025, the U.S. Food and Drug Administration (FDA) issued a Form 483 to Hetero's Nakkapalli facility in Andhra Pradesh, citing six major compliance lapses, including quality control deficiencies and improper documentation practices. Such observations can jeopardize Hetero's ability to supply APIs and antiretroviral drugs to the U.S. market, underscoring the critical need for rigorous adherence to Good Manufacturing Practices (GMP) and prompt corrective actions to address regulatory concerns.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Fenofibrate shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Hetero Labs Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 338 individual customs records matching Hetero Labs Limited exporting Fenofibrate, covering 99 formulations to 10 countries via 29 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 81+ countries, 368+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Fenofibrate

Fenofibrate

Hetero Labs Limited — Fenofibrate Exporter Profile

Hetero Labs Limited — Fenofibrate Export Profile: Buyers & Destinations

Where Does Hetero Labs Limited Export Fenofibrate?

Who Are the Top Buyers of Fenofibrate from Hetero Labs Limited?

What Is India's Total Fenofibrate Export Value and How Much Does Hetero Labs Limited Contribute?

What Is the Average Shipment Value for Hetero Labs Limited's Fenofibrate Exports?

How Does Hetero Labs Limited Compare to Other Indian Fenofibrate Exporters?

What Fenofibrate Formulations Does Hetero Labs Limited Export?

Regulatory Requirements: Exporting Fenofibrate to Key Markets

United States — FDA

Australia — TGA

How Does Hetero Labs Limited Compare to Nearest Fenofibrate Exporters?

Which Indian Ports Ship Fenofibrate Exports?

What Other Lipid & Metabolism Products Does Hetero Labs Limited Export?

Fenofibrate — Export Intelligence Video

Geopolitical & Trade Policy Impact on Hetero Labs Limited's Fenofibrate Exports

Hetero Labs Limited — Regulatory Compliance & Quality Standards

About Hetero Labs Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Fenofibrate Export Data from Hetero Labs Limited

Fenofibrate Stats

Company Overview

Top Products by Hetero Labs Limited

Related Analysis

Need Detailed Export Data?

Data Source